Pharmaceuticals News and Research

RSS

A look at the past and present costs and history of American health care

A couple stories Friday examine just how Americans ended up with a system where employers pick up the tab for health insurance and which groups will end up paying more for health reform.

24 Oct 2009

Bend Research looking for partners to develop oligonucleotide delivery technologies

Bend Research Inc., a company with more than 30 years of experience in applying innovative pharmaceutical technologies to help clients solve their most difficult scientific and technical problems, is marking the one-year anniversary of a new initiative focused on meeting the needs of a broad range of U.S. and international clients.

23 Oct 2009

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

This incidence of counterfeit prescription medicines in Europe's traditional supply chain is growing. This is why EFPIA (European Federation of Pharmaceutical Industries and Associations) has launched a pilot project that includes the testing of a coding and identification solution in Sweden.

23 Oct 2009

IDEXX Laboratories reports increased revenues for 2009 third quarter

IDEXX Laboratories, Inc., today reported that revenues for the third quarter of 2009 were $259.1 million compared to $251.1 million for the third quarter of 2008.

23 Oct 2009

Modified NAGA: New enzyme for enzyme replacement therapy

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

23 Oct 2009

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Medgenics is pleased to announce that it has signed a preclinical development and option agreement with a major international biopharmaceutical company that is a market leader in the field of hemophilia.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.

23 Oct 2009

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014.

23 Oct 2009

UC Riverside researchers create stable "abnormal N-heterocyclic carbenes"

Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.

23 Oct 2009

Ambry Genetics awarded CSP status for Agilent's SureSelect Target Enrichment System

Agilent Technologies Inc. and Ambry Genetics today announced that Ambry is the first organization to achieve Certified Service Provider (CSP) status for Agilent's SureSelect Target Enrichment System for next-generation sequencing.

23 Oct 2009

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

Families of Spinal Muscular Atrophy (FSMA) announced today that it has entered into a groundbreaking exclusive license agreement with Repligen Corporation for the development of a potential treatment of Spinal Muscular Atrophy (SMA).

23 Oct 2009

Pfizer-Wyeth merger analyzed

Drug companies are carefully navigating the current stretch of industry consolidation as giants merge and promising small firms seek interested buyers.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

23 Oct 2009

Twenty charged with Medicare fraud; and such crimes are emerging as a new area for gang activity

Federal authorities have charged 20 people with Medicare fraud in seven different cases. Those charged alledgedly bilked the government out of about $26 million in unneeded or undelivered medical equipment in California and Las Vegas.

23 Oct 2009

New method devised for harvesting purified protein molecules

Drugs based on engineered proteins represent a new frontier for pharmaceutical makers. Even after they discover a protein that may form the basis of the next wonder drug, however, they have to confront a long-standing problem: how to produce large quantities of the protein in a highly pure state.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Pharmaceuticals News and Research

A look at the past and present costs and history of American health care

Bend Research looking for partners to develop oligonucleotide delivery technologies

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

IDEXX Laboratories reports increased revenues for 2009 third quarter

Modified NAGA: New enzyme for enzyme replacement therapy

Medgenics signs $7 million agreement to develop the Biopump technology for Factor VIII

Shire announces new pharmacokinetic data of ADHD medication

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

UC Riverside researchers create stable "abnormal N-heterocyclic carbenes"

Ambry Genetics awarded CSP status for Agilent's SureSelect Target Enrichment System

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

Pfizer-Wyeth merger analyzed

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

In vitro activity results of Cem-101 against gram-positive organisms to be presented

Twenty charged with Medicare fraud; and such crimes are emerging as a new area for gang activity

New method devised for harvesting purified protein molecules

Early diagnostic for ovarian cancer to be developed

Event guide: World ADC London eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring